Arbutus Biopharma Corp Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Arbutus Biopharma Corp stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $2.12M, a 368.65% increase year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $12.56M, a 373.28% increase year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $794.00K, a 329.19% increase year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $453.00K, a 77.47% decline year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, stock options exercised for fiscal 2025 was $5.54M, a 25.91% decline from fiscal 2024.
- Arbutus Biopharma Corp stock issued during period, value, stock options exercised for fiscal 2024 was $7.48M, a 2775.77% increase from fiscal 2023.
- Arbutus Biopharma Corp stock issued during period, value, stock options exercised for fiscal 2023 was $260.00K, a 113.11% increase from fiscal 2022.
- Arbutus Biopharma Corp stock issued during period, value, stock options exercised for fiscal 2022 was $122.00K, a 94.22% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $2.12M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $12.56M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $5.54M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $794.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $453.00K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $2.65M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $7.48M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $185.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $2.01M 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $2.45M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $260.00K 10-K · filed 2025-03-27 | |
| 2023-03-31 | $259.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $122.00K 10-K · filed 2024-03-05 | |
| 2022-06-30 | $113.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $8.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $2.11M 10-K · filed 2023-03-02 | |
| 2021-09-30 | $2.00M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $15.00K 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $208.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $449.00K 10-K · filed 2022-03-03 | |
| 2020-09-30 | $336.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$86.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $166.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $307.00K 10-K · filed 2021-03-04 | |
| 2019-06-30 | $2.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $288.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $1.38M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $434.00K 10-Q · filed 2019-11-06 | $1.31M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $735.00K 10-Q · filed 2019-11-06 | $1.05M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-03-31 | $103.00K 10-Q · filed 2019-11-06 | $315.00K derived: sum of 4 quarters · filed 2019-11-06 |
| 2017-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $213.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $174.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $179.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $147.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-03-31 | $1.00K 10-Q · filed 2017-05-04 | $144.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $258.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $234.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $208.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | $115.00K 10-Q · filed 2016-05-04 | $1.15M derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $1.65M 10-K · filed 2018-03-16 |
| 2015-09-30 | $116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.95M derived: sum of 4 quarters · filed 2017-03-22 |
| 2015-06-30 | $939.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $2.10M derived: sum of 4 quarters · filed 2017-03-22 |
| 2015-03-31 | $620.00K 10-Q · filed 2015-05-06 | $1.31M derived: sum of 4 quarters · filed 2017-03-22 |
| 2014-12-31 | $276.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $2.62M 10-K · filed 2017-03-22 |
| 2014-09-30 | $268.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | |
| 2014-06-30 | $148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | |
| 2014-03-31 | $1.92M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $389.00K 10-K · filed 2016-03-09 | |
| 2012-12-31 | 71.05K CAD 20-F · filed 2013-03-27 | |
| 2012-12-31 | $71.00K 10-K · filed 2015-03-13 | |
| 2011-12-31 | 10.66K CAD 20-F · filed 2013-03-27 | |
| 2011-12-31 | $10.79K 10-K · filed 2014-03-28 | |
| 2010-12-31 | 34.91K CAD 20-F · filed 2013-03-27 | |
| 2009-12-31 | 7.89K CAD 20-F · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |